Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children
- PMID: 20689955
- DOI: 10.1007/s00381-010-1255-2
Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children
Abstract
Background and purpose: Based on the time until treatment failure, we retrospectively analyzed 389 children to compare the long-term effectiveness of first-line antiepileptic drugs (AEDs) in children with generalized onset or unclassified epileptic seizures.
Methods: Analyses were based on time until treatment failure and time until remission.
Results: In terms of time until treatment failure, the failure rates of topiramate and carbamazepine were higher than that of sodium valproate (p < 0.05). For time until 1-year remission, sodium valproate was found to be significantly better than either topiramate or carbamazepine (p < 0.05). For the subgroup with generalized onset epilepsy, sodium valproate was much better than either topiramate or carbamazepine (p < 0.05). No significant differences were found between topiramate and carbamazepine (p = 0.319). For unclassified epileptic seizures, no significant differences were found among the three AEDs.
Conclusion: Sodium valproate should be the drug of choice for patients with children with generalized onset, and no significant differences were found among the three AEDs in unclassified epileptic seizures.
Similar articles
-
Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2019 Jun 24;6(6):CD012065. doi: 10.1002/14651858.CD012065.pub3. Cochrane Database Syst Rev. 2019. PMID: 31233229 Free PMC article.
-
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134. doi: 10.3310/hta11370. Health Technol Assess. 2007. PMID: 17903391 Clinical Trial.
-
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.Lancet. 2007 Mar 24;369(9566):1016-26. doi: 10.1016/S0140-6736(07)60461-9. Lancet. 2007. PMID: 17382828 Free PMC article. Clinical Trial.
-
Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy.J Child Neurol. 2004 Feb;19(2):135-41. doi: 10.1177/08830738040190020901. J Child Neurol. 2004. PMID: 15072107 Clinical Trial.
-
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2019 Jul 18;7(7):CD001911. doi: 10.1002/14651858.CD001911.pub4. Cochrane Database Syst Rev. 2019. PMID: 31318037 Free PMC article.
Cited by
-
Outcomes of sustained-release formulation of valproate and topiramate monotherapy in patients with epilepsy: a multi-centre, cohort study.PLoS One. 2012;7(12):e47982. doi: 10.1371/journal.pone.0047982. Epub 2012 Dec 11. PLoS One. 2012. PMID: 23239963 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical